Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Malaria Vaccines
Report summarizes malaria vaccines study findings from Emory University, Emory Vaccine Center
April 22nd, 2009
"Synthetic linear peptide chimeras (LPCscys +) show promise as delivery platforms for malaria subunit vaccines. Maximal immune response to LPCscys + in rodent malaria models depends upon formation of cross-linkages to generate homopolymers, presenting challenges for vaccine production," scientists writing in the journal Microbes and Infection report. "To replicate the immunogenicity of LPCscys + using a recombinant approach, we designed a recombinant LPC (rLPC) based on Plasmodium yoelii circumsporozoite protein-specific sequences of 208 amino acids consisting of four LPC subunits in series. BALB/c or CAF1/J mice were immunized with synthetic or recombinant LPCs....
Source: Vaccine Weekly (2009-04-22)
|
